Function, structure and therapeutic potential of complement C5a receptors

British Journal of Pharmacology

Volumn 152, Issue 4, 2007, Pages 429-448

  Monk, P N ^a   Scola, A M ^a   Madala, P ^b   Fairlie, D P ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antagonist; C5a; Complement; G protein; Immunity; Inflammation; Receptor

Indexed keywords

3D53; AMINOQUINOLINE DERIVATIVE; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; CYCLOPEPTIDE; ECULIZUMAB; GUANIDINE DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDANTOIN; JPE 1375; JSM 7431; JSM 7717; L 156602; NDT 9520492; NGD 2000 1; PERTUSSIS TOXIN; PHENYLGUANIDINE DERIVATIVE; PMX 53; RPR 121154; SYNTHETIC PEPTIDE; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG; W 54011;

ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGY; ANAPHYLAXIS; ANTIPHOSPHOLIPID SYNDROME; ASTHMA; ATHEROSCLEROSIS; BINDING SITE; CELL TYPE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; ENTERITIS; GLOMERULONEPHRITIS; GRAFT REJECTION; HEART MUSCLE FIBROSIS; HEMOLYTIC ANEMIA; HEMORRHAGIC SHOCK; HUMAN; HUNTINGTON CHOREA; IMMUNITY; IMMUNOREGULATION; INFECTION; INFLAMMATION; INFLAMMATORY DISEASE; INFLUENZA; KNOCKOUT MOUSE; LIGAND BINDING; LIVER INJURY; LUNG INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOLECULAR MODEL; NEUROLOGIC DISEASE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTON NUCLEAR MAGNETIC RESONANCE; PSORIASIS; REPERFUSION INJURY; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; SPONTANEOUS ABORTION; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; COMPLEMENT C5A; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTOR, ANAPHYLATOXIN C5A;

EID: 35348821843     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707332     Document Type: Review

References (259)

1. Abe M, Shibata K, Akatsu H, Shimizu N, Sakata N, Katsuragi T et al. (2001). Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. J Immunol 167: 4651-4660.
2. Albizu L, Balestre MN, Breton C, Pin JP, Manning M, Mouillac B et al. (2006). Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding. Mol Pharmacol 70: 1783-1791.
3. Ali H, Fisher I, Haribabu B, Richardson RM, Snyderman R (1997). Role of phospholipase Cbeta3 phosphorylation in the desensitization of cellular responses to platelet-activating factor. J Biol Chem 272: 11706-11709.
4. Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, Taylor SM (2003). A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int 63: 134-142.
5. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM (2004). The role of the complement system in ischemia-reperfusion injury. Shock 21: 401-409.
6. Arumugam TV, Shiels IA, Woodruff TM, Reid RC, Fairlie DP, Taylor SM (2002). Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res 103: 260-267.
7. Astles PC, Brown TJ, Cox P, Halley F, Lockey PM, Mccarthy C et al. (1997). New non-peptidic C5a receptor antagonists. Bioorg Med Chem Lett 7: 907-912.
8. Auger GA, Smith BM, Pease JE, Barker MD (2004). The use of membrane translocating peptides to identify sites of interaction between the C5a receptor and downstream effector proteins. Immunology 112: 590-596.
9. Baelder R, Fuchs B, Bautsch W, Zwirner J, Kohl J, Hoymann HG et al. (2005). Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol 174: 783-789.
10. Ballesteros J, Palczewski K (2001). G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr Opin Drug Discov Devel 4: 561-574.
11. Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ (2005). C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 35: 2496-2506.
12. Baranski TJ, Herzmark P, Lichtarge O, Gerber BO, Trueheart J, Meng EC et al. (1999). C5a receptor activation. Genetic identification of critical residues in four transmembrane helices. J Biol Chem 274: 15757-15765.
13. Barnes KC, Caraballo L, Munoz M, Zambelli-Weiner A, Ehrlich E, Burki M et al. (2004). A novel promoter polymorphism in the gene encoding complement component 5 receptor 1 on chromosome 19q13.3 is not associated with asthma and atopy in three independent populations. Clin Exp Allergy 34: 736-744.
14. Becker EL (1972). The relationship of the chemotactic behavior of the complement-derived factors, C3a, C5a, and C567, and a bacterial chemotactic factor to their ability to activate the proesterase 1 of rabbit polymorphonuclear leukocytes. J Exp Med 135: 376-387.
15. Bhatia M (2002). Novel therapeutic targets for acute pancreatitis and associated multiple organ dysfunction syndrome. Curr Drug Targets Inflamm Allergy 1: 343-351.
16. Birney E, Andrews D, Caccamo M, Chen Y, Clarke L, Coates G et al. (2006). Ensembl 2006. Nucleic Acids Res 34: D556-D561.
17. Bock D, Martin U, Gartner S, Rheinheimer C, Raffetseder U, Arseniev L et al. (1997). The C terminus of the human C5a receptor (CD88) is required for normal ligand-dependent receptor internalization. Eur J Immunol 27: 1522-1529.
18. Bokisch VA, Muller-Eberhard HJ (1970). Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest 49: 2427-2436.
19. Bokoch GM (2003). Biology of the p21-activated kinases. Annu Rev Biochem 72: 743-781.
20. Borders CW, Courtney A, Ronen K, Pilar Laborde-Lahoz M, Guidry TV, Hwang SA et al. (2005). Requisite role for complement C5 and the C5a receptor in granulomatous response to mycobacterial glycolipid trehalose 6,6′-dimycolate. Scand J Immunol 62: 123-130.
21. Bordet J (1895). Les leukocytes et les proprietes actives du serum chez les vaccines. Ann Inst Pasteur 9: 462.
22. Boulay F, Mery L, Tardif M, Brouchon L, Vignais P (1991). Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochemistry 30: 2993-2999.
23. Bozic CR, Lu B, Hopken UE, Gerard C, Gerard NP (1996). Neurogenic amplification of immune complex inflammation. Science 273: 1722-1725.
24. Braun L, Christophe T, Boulay F (2003). Phosphorylation of key serine residues is required for internalization of the complement 5a (C5a) anaphylatoxin receptor via a beta-arrestin, dynamin, and clathrin-dependent pathway. J Biol Chem 278: 4277-4285.
25. Braun M, Davis III AE (1998). Cultured human glomerular mesangial cells express the C5a receptor. Kidney Int 54: 1542-1549.
26. Bubeck P, Grotzinger J, Winkler M, Kohl J, Wollmer A, Klos A et al. (1994). Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Eur J Biochem 219: 897-904.
27. Buchner RR, Hugli TE, Ember JA, Morgan EL (1995). Expression of functional receptors for human C5a anaphylatoxin (CD88) on the human hepatocellular carcinoma cell line HepG2. Stimulation of acute-phase protein-specific mRNA and protein synthesis by human C5a anaphylatoxin. J Immunol 155: 308-315.
28. Buck E, Wells JA (2005). Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor. Proc Natl Acad Sci USA 102: 2719-2724.
29. Buck E, Bourne H, Wells JA (2005). Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor. J Biol Chem 280: 4009-4012.
30. Buhl AM, Avdi N, Worthen GS, Johnson GL (1994). Mapping of the C5a receptor signal transduction network in human neutrophils. Proc Natl Acad Sci USA 91: 9190-9194.
31. Burg M, Martin U, Bock D, Rheinheimer C, Kohl J, Bautsch W et al. (1996). Differential regulation of the C3a and C5a receptors (CD88) by IFN-gamma and PMA in U937 cells and related myeloblastic cell lines. J Immunol 157: 5574-5581.
32. Cain SA, Monk PN (2002). The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J Biol Chem 277: 7165-7169.
33. Cain SA, Coughlan T, Monk PN (2001). Mapping the ligand-binding site on the C5a receptor: arginine74 of C5a contacts aspartate282 of the C5a receptor. Biochemistry 40: 14047-14052.
34. Cain SA, Higginbottom A, Monk PN (2003). Characterisation of C5a receptor agonists from phage display libraries. Biochem Pharmacol 66: 1833-1840.
35. Chalmers DK, Marshall GR (1995). Pro-DNMe-amino acid and D-Pro-NMe-amino acid - simple, efficient reverse-turn constraints. J Am Chem Soc 117: 5927-5937.
36. Chen NJ, Mirtsos C, Suh D, Lu YC, Lin WJ, Mckerlie C et al. (2007). C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 446: 203-207.
37. Chen Z, Zhang X, Gonnella NC, Pellas TC, Boyar WC, Ni F (1998). Residues 21-30 within the extracellular N-terminal region of the C5a receptor represent a binding domain for the C5a anaphylatoxin. J Biol Chem 273: 10411-10419.
38. Christophe T, Rabiet MJ, Tardif M, Milcent MD, Boulay F (2000). Human complement 5a (C5a) anaphylatoxin receptor (CD88) phosphorylation sites and their specific role in receptor phosphorylation and attenuation of G protein-mediated responses. Desensitization of C5a receptor controls superoxide production but not receptor sequestration in HL-60 cells. J Biol Chem 275: 1656-1664.
39. Condliffe AM, Webb LM, Ferguson GJ, Davidson K, Turner M, Vigorito E et al. (2006). RhoG regulates the neutrophil NADPH oxidase. J Immunol 176: 5314-5320.
40. Connelly MA, Moulton RA, Smith AK, Lindsey DR, Sinha M, Wetsel RA et al. (2006). Mycobacteria-primed macrophages and dendritic cells induce an up-regulation of complement C5a anaphylatoxin receptor (CD88) in CD3+ murine T cells. J Leukoc Biol 81: 212-220.
41. Crass T, Ames RS, Sarau HM, Tornetta MA, Foley JJ, Kohl J et al. (1999a). Chimeric receptors of the human C3a receptor and C5a receptor (CD88). J Biol Chem 274: 8367-8370.
42. Crass T, Bautsch W, Cain SA, Pease JE, Monk PN (1999b). Receptor activation by human C5a des Arg74 but not intact C5a is dependent on an interaction between Glu199 of the receptor and Lys68 of the ligand. Biochemistry 38: 9712-9717.
43. Daveau M, Benard M, Scotte M, Schouft MT, Hiron M, Francois A et al. (2004). Expression of a functional C5a receptor in regenerating hepatocytes and its involvement in a proliferative signaling pathway in rat. J Immunol 173: 3418-3424.
44. De Laszlo SE, Allen EE, Li B, Ondeyka D, Rivero R, Malkowitz L et al. (1997). A nonpeptidic agonist ligand of the human C5a receptor: Synthesis, binding affinity optimization and functional characterization. Bioorg Med Chem Lett 7: 213-218.
45. Demartino JA, Van Riper G, Siciliano SJ, Molineaux CJ, Konteatis ZD, Rosen H et al. (1994). The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs. J Biol Chem 269: 14446-14450.
46. Denecke B, Meyerdierks A, Bottger EC (1999). RGS1 is expressed in monocytes and acts as a GTPase-activating protein for G-protein-coupled chemoattractant receptors. J Biol Chem 274: 26860-26868.
47. Drapeau G, Brochu S, Godin D, Levesque L, Rioux F, Marceau F (1993). Synthetic C5a receptor agonists. Pharmacology, metabolism and in vivo cardiovascular and hematologic effects. Biochem Pharmacol 45: 1289-1299.
48. Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, Mccray Jr PB et al. (2001). Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 166: 2025-2032.
49. El-Naggar AK, Van Epps DE, Williams Jr RC (1980). Human-B and T-lymphocyte locomotion in response to casein, C5a, and f-met-leu-phe. Cell Immunol 56: 365-373.
50. Fairlie DP, Abbenante G, March DR (1995). Macrocyclic peptidomimetics - forcing peptides into bioactive conformations. Curr Med Chem 2: 654-686.
51. Falk W, Leonard EJ (1980). Human monocyte chemotaxis: migrating cells are a subpopulation with multiple chemotaxin specificities on each cell. Infect Immun 29: 953-959.
52. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Kuhn J, Gerard C et al. (2001). Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor. J Exp Med 193: 1059-1066.
53. Fayyazi A, Sandau R, Duong LQ, Gotze O, Radzun HJ, Schweyer S et al. (1999). C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. Am J Pathol 154: 495-501.
54. Fayyazi A, Scheel O, Werfel T, Schweyer S, Oppermann M, Gotze O et al. (2000). The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells. Immunology 99: 38-45.
55. Fick Jr RB, Robbins RA, Squier SU, Schoderbek WE, Russ WD (1986). Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity. Pediatr Res 20: 1258-1268.
56. Finch AM, Vogen SM, Sherman SA, Kirnarsky L, Taylor SM, Sanderson SD (1997). Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity. J Med Chem 40: 877-884.
57. Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP et al. (1999). Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem 42: 1965-1974.
58. Fleming SD, Mastellos D, Karpel-Massler G, Shea-Donohue T, Lambris JD, Tsokos GC (2003). C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injury. Clin Immunol 108: 263-273.
59. Floreani AA, Heires AJ, Welniak LA, Miller-Lindholm A, Clark-Pierce L, Rennard SI et al. (1998). Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke. J Immunol 160: 5073-5081.
60. Floyd DH, Geva A, Bruinsma SP, Overton MC, Blumer KJ, Baranski TJ (2003). C5a receptor oligomerization. II. Fluorescence resonance energy transfer studies of a human G protein-coupled receptor expressed in yeast. J Biol Chem 278: 35354-35361.
61. Francis K, Lewis BM, Monk PN, Scanlon MF, Ham J (2005). Complement C5a receptors are expressed throughout the anterior pituitary gland. Endocrine Abstracts 9: 126.
62. Friedberger E (1910). Weitere untersuchungen uber Eisissanaphylaxie: IV. Mitteilung. Immunitaetaforsch Exp Ther 4: 636-690.
63. Fukuoka Y, Medof EM (2001). C5a receptor-mediated production of IL-8 by the human retinal pigment epithelial cell line, ARPE-19. Curr Eye Res 23: 320-325.
64. Gaca JG, Appel III JZ, Lukes JG, Gonzalez-Stawinski GV, Lesher A, Palestrant D et al. (2006). Effect of an anti-C5a monoclonal antibody indicates a prominent role for anaphylatoxin in pulmonary xenograft dysfunction. Transplantation 81: 1686-1694.
65. Gao H, Neff TA, Guo RF, Speyer CL, Sarma JV, Tomlins S et al. (2005). Evidence for a functional role of the second C5a receptor C5L2. FASEB J 19: 1003-1005.
66. Gasque P, Singhrao SK, Neal JW, Gotze O, Morgan BP (1997). Expression of the receptor for complement C5a (CD88) is upregulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 150: 31-41.
67. Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, Fontaine M et al. (1998). The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol 160: 3543-3554.
68. Gavrilyuk V, Kalinin S, Hilbush BS, Middlecamp A, Mcguire S, Pelligrino D et al. (2005). Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of anti-inflammatory properties. J Neurochem 92: 1140-1149.
69. Gerard NP, Bao L, Xiao-Ping H, Eddy Jr RL, Shows TB, Gerard C (1993). Human chemotaxis receptor genes cluster at 19q13.3-13.4. Characterization of the human C5a receptor gene. Biochemistry 32: 1243-1250.
70. Gerard NP, Gerard C (1991). The chemotactic receptor for human C5a anaphylatoxin. Nature 349: 614-617.
71. Gerard NP, Gerard C (2002). Complement in allergy and asthma. Curr Opin Immunol 14: 705-708.
72. Gerard NP, Lu B, Liu P, Craig S, Fujiwara Y, Okinaga S et al. (2005). An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem 280: 39677-39680.
73. Gerber BO, Meng EC, Dotsch V, Baranski TJ, Bourne HR (2001a). An activation switch in the ligand binding pocket of the C5a receptor. J Biol Chem 276: 3394-3400.
74. Gerber BO, Meng EC, Dotsch V, Baranski TJ, Bourne HR (2001b). An activation switch in the ligand binding pocket of the C5a receptor. J Biol Chem 276: 3394-3400.
75. Geva A, Lassere TB, Lichtarge O, Pollitt SK, Baranski TJ (2000). Genetic mapping of the human C5a receptor. Identification of transmembrane amino acids critical for receptor function. J Biol Chem 275: 35393-35401.
76. Giannini E, Brouchon L, Boulay F (1995). Identification of the major phosphorylation sites in human C5a anaphylatoxin receptor in vivo. J Biol Chem 270: 19166-19172.
77. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D et al. (2003). Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112: 1644-1654.
78. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE (2006). Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 203: 2165-2175.
79. Godau J, Heller T, Hawlisch H, Trappe M, Howells E, Best J et al. (2004). C5a initiates the inflammatory cascade in immune complex peritonitis. J Immunol 173: 3437-3445.
80. Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP (1997). Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clin Exp Immunol 110: 45-52.
81. Governa M, Amati M, Fenoglio I, Valentino M, Coloccini S, Bolognini L et al. (2005). Variability of biological effects of silicas: different degrees of activation of the fifth component of complement by amorphous silicas. Toxicol Appl Pharmacol 208: 68-77.
82. Governa M, Amati M, Valentino M, Visona I, Fubini B, Botta GC et al. (2000). In vitro cleavage by asbestos fibers of the fifth component of human complement through free-radical generation and kallikrein activation. J Toxicol Environ Health A 59: 539-552.
83. Grant EP, Picarella D, Burwell T, Delaney T, Croci A, Avitahl N et al. (2002). Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J Exp Med 196: 1461-1471.
84. Gurevich VV, Gurevich EV (2006). The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ther 110: 465-502.
85. Gutzmer R, Kother B, Zwirner J, Dijkstra D, Purwar R, Wittmann M et al. (2006). Human Plasmacytoid Dendritic Cells Express Receptors for Anaphylatoxins C3a and C5a and Are Chemoattracted to C3a and C5a. J Invest Dermatol 111: 435-443.
86. Hagemann IS, Narzinski KD, Floyd DH, Baranski TJ (2006). Random mutagenesis of the C5A receptor amino terminus provides a structural constraint for C5A docking. J Biol Chem 281: 36783-36792.
87. Hammerschmidt DE, Bowers TK, Lammi-Keefe CJ, Jacob HS, Craddock PR (1980a). Granulocyte aggregometry: a sensitive technique for the detection of C5a and complement activation. Blood 55: 898-902.
88. Hammerschmidt DE, Greenberg CS, Yamada O, Craddock PR, Jacob HS (1981). Cholesterol and atheroma lipids activate complement and stimulate granulocytes. A possible mechanism for amplification of ischemic injury in atherosclerotic states. J Lab Clin Med 98: 68-77.
89. Hammerschmidt DE, Weaver LJ, Hudson LD, Craddock PR, Jacob HS (1980b). Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value. Lancet 1: 947-949.
90. Harkin DW, Romaschin A, Taylor SM, Rubin BB, Lindsay TF (2004). Complement C5a receptor antagonist attenuates multiple organ injury in a model of ruptured abdominal aortic aneurysm. J Vasc Surg 39: 196-206.
91. Haviland DL, Mccoy RL, Whitehead WT, Akama H, Molmenti EP, Brown A et al. (1995). Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J Immunol 154: 1861-1869.
92. Hawlisch H, Belkaid Y, Baelder R, Hildeman D, Gerard C, Kohl J (2005). C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 22: 415-426.
93. Haynes DR, Harkin DG, Bignold LP, Hutchens MJ, Taylor SM, Fairlie DP (2000). Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist. Biochem Pharmacol 60: 729-733.
94. Higginbottom A, Cain SA, Woodruff TM, Proctor LM, Madala PK, Tyndall JD et al. (2005). Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site. J Biol Chem 280: 17831-17840.
95. Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A et al. (2005). Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 37: 835-843.
96. Hook WA, Siraganian RP, Wahl SM (1975). Complement-induced histamine release from human basophils. I. Generation of activity in human serum. J Immunol 114: 1185-1190.
97. Hopken UE, Lu B, Gerard NP, Gerard C (1996). The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383: 86-89.
98. Hopken UE, Lu B, Gerard NP, Gerard C (1997). Impaired inflammatory responses in the reverse arthus reaction through genetic deletion of the C5a receptor. J Exp Med 186: 749-756.
99. Hsu W, Rosenquist GL, Ansari AA, Gershwin ME (2005). Autoimmunity and tyrosine sulfation. Autoimmun Rev 4: 429-435.
100. Huang R, Lian JP, Robinson D, Badwey JA (1998). Neutrophils stimulated with a variety of chemoattractants exhibit rapid activation of p21-activated kinases (Paks): separate signals are required for activation and inactivation of paks. Mol Cell Biol 18: 7130-7138.
101. Huber-Lang MS, Riedeman NC, Sarma JV, Younkin EM, Mcguire SR, Laudes IJ et al. (2002). Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 16: 1567-1574.
102. Huber-Lang M, Sarma JV, Rittirsch D, Schreiber H, Weiss M, Flierl M et al. (2005). Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans. J Immunol 174: 1104-1110.
103. Huey R, Hugli TE (1985). Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN). J Immunol 135: 2063-2068.
104. Hunt JR, Martin CB, Martin BK (2005). Transcriptional regulation of the murine C5a receptor gene: NF-Y is required for basal and LPS induced expression in macrophages and endothelial cells. Mol Immunol 42: 1405-1415.
105. Huttenrauch F, Pollok-Kopp B, Oppermann M (2005). G protein-coupled receptor kinases promote phosphorylation and beta-arrestin-mediated internalization of CCR5 homo- and hetero-oligomers. J Biol Chem 280: 37503-37515.
106. Hwang JI, Choi S, Fraser ID, Chang MS, Simon MI (2005). Silencing the expression of multiple Gbeta-subunits eliminates signaling mediated by all four families of G proteins. Proc Natl Acad Sci USA 102: 9493-9498.
107. Hwang JI, Fraser ID, Choi S, Qin XF, Simon MI (2004). Analysis of C5a-mediated chemotaxis by lentiviral delivery of small interfering RNA. Proc Natl Acad Sci USA 101: 488-493.
108. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA et al. (2002). Arthritis critically dependent on innate immune system players. Immunity 16: 157-168.
109. Jiang H, Kuang Y, Wu Y, Smrcka A, Simon MI, Wu D (1996). Pertussis toxin-sensitive activation of phospholipase C by the C5a and fMet-Leu-Phe receptors. J Biol Chem 271: 13430-13434.
110. Johswich K, Martin M, Thalmann J, Rheinheimer C, Monk PN, Klos A (2006). Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell-lines. J Biol Chem 281: 39088-39095.
111. Jones HA, Schofield JB, Krausz T, Boobis AR, Haslett C (1998). Pulmonary fibrosis correlates with duration of tissue neutrophil activation. Am J Respir Crit Care Med 158: 620-628.
112. Joost P, Methner A (2002). Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands. Genome Biol 3: research0063.1-research0063.16.
113. Kalant D, Cain SA, Maslowska M, Sniderman AD, Cianflone K, Monk PN (2003). The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J Biol Chem 278: 11123-11129.
114. Kapp A, Schopf E (1985). Involvement of complement in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 114: 152-154.
115. Kawai M, Quincy DA, Lane B, Mollison KW, Luly JR, Carter GW (1991). Identification and synthesis of a receptor binding site of human anaphylatoxin C5a. J Med Chem 34: 2068-2071.
116. Kawai M, Wiedeman PE, Luly JR, Or YS (1992). New hexa - and heptapeptides are anaphylatoxin antagonists and agonists - for treating inflammatory and immunodeficiency diseases, cancers and severe infections. World Intellectual Property Organisation W092/12168-A1.
117. Kay AB, Shin HS, Austen KF (1973). Selective attraction of eosinophils and synergism between eosinophil chemotactic factor of anaphylaxis (ECF-A) and a fragment cleaved from the fifth component of complement (C5a). Immunology 24: 969-976.
118. Kiener HP, Baghestanian M, Dominkus M, Walchshofer S, Ghannadan M, Willheim M et al. (1998). Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum 41: 233-245.
119. Kijlstra A, La Heij E, Hendrikse F (2005). Immunological factors in the pathogenesis and treatment of age-related macular degeneration. Ocul Immunol Inflamm 13: 3-11.
120. Kim AH, Dimitriou ID, Holland MC, Mastellos D, Mueller YM, Altman JD et al. (2004). Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses. J Immunol 173: 2524-2529.
121. Klco JM, Lassere TB, Baranski TJ (2003). C5a receptor oligomerization. I. Disulfide trapping reveals oligomers and potential contact surfaces in a G protein-coupled receptor. J Biol Chem 278: 35345-35353.
122. Klco JM, Nikiforovich GV, Baranski TJ (2006). Genetic analysis of the first and third extracellular loops of the C5a receptor reveals an essential WXFG motif in the first loop. J Biol Chem 281: 12010-12019.
123. Klco JM, Wiegand CB, Narzinski K, Baranski TJ (2005). Essential role for the second extracellular loop in C5a receptor activation. Nat Struct Mol Biol 12: 320-326.
124. Kohl J (2006). Drug evaluation: the C5a receptor antagonist PMX-53. Curr Opin Mol Ther 8: 529-538.
125. Kohl J, Wills-Karp M (2007). Complement regulates inhalation tolerance at the dendritic cell/T cell interface. Mol Immunol 44: 44-56.
126. Kohl J, Baelder R, Lewkowich IP, Pandey MK, Hawlisch H, Wang L et al. (2006). A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest 116: 783-796.
127. Kolakowski Jr LF, Lu B, Gerard C, Gerard NP (1995). Probing the 'message:address' sites for chemoattractant binding to the C5a receptor. Mutagenesis of hydrophilic and proline residues within the transmembrane segments. J Biol Chem 270: 18077-18082.
128. Koleva M, Schlaf G, Landmann R, Gotze O, Jungermann K, Schieferdecker HL (2002). Induction of anaphylatoxin C5a receptors in rat hepatocytes by lipopolysaccharide in vivo: mediation by interleukin-6 from Kupffer cells. Gastroenterology 122: 697-708.
129. Kondo C, Mizuno M, Nishikawa K, Yuzawa Y, Hotta N, Matsuo S (2001). The role of C5a in the development of thrombotic glomerulonephritis in rats. Clin Exp Immunol 124: 323-329.
130. Konteatis ZD, Siciliano SJ, Van Riper G, Molineaux CJ, Pandya S, Fischer P et al. (1994). Development of C5a receptor antagonists. Differential loss of functional responses. J Immunol 153: 4200-4205.
131. Kupp LI, Kosco MH, Schenkein HA, Tew JG (1991). Chemotaxis of germinal center B cells in response to C5a. Eur J Immunol 21: 2697-2701.
132. Kuroki M, O'Flaherty JT (1999). Extracellular signal-regulated protein kinase (ERK)-dependent and ERK-independent pathways target STAT3 on serine-727 in human neutrophils stimulated by chemotactic factors and cytokines. Biochem J 341 (Part 3): 691-696.
133. La Sala A, Gadina M, Kelsall BL (2005). G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK. J Immunol 175: 2994-2999.
134. Lambrecht BN (2006). An unexpected role for the anaphylatoxin C5a receptor in allergic sensitization. J Clin Invest 116: 628-632.
135. Langkabel P, Zwirner J, Oppermann M (1999). Ligand-induced phosphorylation of anaphylatoxin receptors C3aR and C5aR is mediated by 'G protein-coupled receptor kinases. Eur J Immunol 29: 3035-3046.
136. Lanza TJ, Durette PL, Rollins T, Siciliano S, Cianciarulo DN, Kobayashi SV et al. (1992). Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding. J Med Chem 35: 252-258.
137. Laskin DL, Pilaro AM (1986). Potential role of activated macrophages in acetaminophen hepatotoxicity. I. Isolation and characterization of activated macrophages from rat liver. Toxicol Appl Pharmacol 86: 204-215.
138. Laudes IJ, Chu JC, Huber-Lang M, Guo RF, Riedemann NC, Sarma JV et al. (2002). Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol 169: 5962-5970.
139. Lawrence ID, Warner JA, Cohan VL, Hubbard WC, Kagey-Sobotka A, Lichtenstein LM (1987). Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. J Immunol 139: 3062-3069.
140. Lee DK, George SR, Cheng R, Nguyen T, Liu Y, Brown M et al. (2001). Identification of four novel human G protein-coupled receptors expressed in the brain. Brain Res Mol Brain Res 86: 13-22.
141. Lee H, Zahra D, Vogelzang A, Newton R, Thatcher J, Quan A et al. (2006). Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Nat Biotechnol 24: 1279-1284.
142. Li Z, Hannigan M, Mo Z, Liu B, Lu W, Wu Y et al. (2003). Directional sensing requires G beta gamma-mediated PAK1 and PIX alpha-dependent activation of Cdc42. Cell 114: 215-227.
143. Lo RK, Cheung H, Wong YH (2003). Constitutively active Galpha16 stimulates STAT3 via a c-Src/JAK- and ERK-dependent mechanism. J Biol Chem 278: 52154-52165.
144. Marc MM, Korosec P, Kosnik M, Kern I, Flezar M, Suskovic S et al. (2004). Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma. Am J Respir Cell Mol Biol 31: 216-219.
145. March DR, Proctor LM, Stoermer MJ, Sbaglia R, Abbenante G, Reid RC et al. (2004). Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol Pharmacol 65: 868-879.
146. Martin CB, Ingersoll SA, Martin BK (2006). Regulation of the C5a receptor promoter in glial cells: Minimal dependence upon the CCAAT element in astrocytes. Mol Immunol 44: 713-721.
147. Martin SE, Chenoweth DE, Engler RL, Roth DM, Longhurst JC (1988). C5a decreases regional coronary blood flow and myocardial function in pigs: implications for a granulocyte mechanism. Circ Res 63: 483-491.
148. Maruo K, Akaike T, Ono T, Okamoto T, Maeda H (1997). Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease. J Allergy Clin Immunol 100: 253-260.
149. Mastellos D, Papadimitriou JC, Franchini S, Tsonis PA, Lambris JD (2001). A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J Immunol 166: 2479-2486.
150. Matsumoto ML, Narzinski K, Kiser PD, Nikiforovich GV, Baranski TJ (2007a). A comprehensive structure-function map of the intracellular surface of the human C5a receptor: I. Identification of critical residues. J Biol Chem 282: 3105-3121.
151. Matsumoto ML, Narzinski K, Nikiforovich GV, Baranski TJ (2007b). A comprehensive structure-function map of the intracellular surface of the human C5a receptor: II. Elucidation of G protein specificity determinants. J Biol Chem 282: 3122-3133.
152. Mazaki Y, Hashimoto S, Tsujimura T, Morishige M, Hashimoto A, Aritake K et al. (2006). Neutrophil direction sensing and superoxide production linked by the GTPase-activating protein GIT2. Nat Immunol 7: 724-731.
153. McCarthy K, Henson PM (1979). Induction of lysosomal enzyme secretion by alveolar macrophages in response to the purified complement fragments C5a and C5a des-arg. J Immunol 123: 2511-2517.
154. McCoy R, Haviland DL, Molmenti EP, Ziambaras T, Wetsel RA, Perlmutter DH (1995). N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation. J Exp Med 182: 207-217.
155. Mery L, Boulay F (1993). Evidence that the extracellular N-terminal domain of C5aR contains amino-acid residues crucial for C5a binding. Eur J Haematol 51: 282-287.
156. Mery L, Boulay F (1994). The NH2-terminal region of C5aR but not that of FPR is critical for both protein transport and ligand binding. J Biol Chem 269: 3457-3463.
157. Milcent MD, Christophe T, Rabiet MJ, Tardif M, Boulay F (1999). Overexpression of wild-type and catalytically inactive forms of GRK2 and GRK6 fails to alter the agonist-induced phosphorylation of the C5a receptor (CD88): evidence that GRK6 is autophosphorylated in COS-7 cells. Biochem Biophys Res Commun 259: 224-229.
158. Milligan G, Ramsay D, Pascal G, Carrillo JJ (2003). GPCR dimerisation. Life Sci 74: 181-188.
159. Mirkovic S, Seymour AM, Fenning A, Strachan A, Margolin SB, Taylor SM et al. (2002). Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 135: 961-968.
160. Mohr M, Hopken U, Oppermann M, Mathes C, Goldmann K, Siever S et al. (1998). Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. Eur J Clin Invest 28: 227-234.
161. Monk PN, Partridge LJ (1993). Characterization of a complement-fragment- C5a-stimulated calcium-influx mechanism in U937 monocytic cells. Biochem J 295 (Part 3): 679-684.
162. Monk PN, Barker MD, Partridge LJ, Pease JE (1995). Mutation of glutamate 199 of the human C5a receptor defines a binding site for ligand distinct from the receptor N terminus. J Biol Chem 270: 16625-16629.
163. Monk PN, Pease JE, Barker MD (1994a). C5a stimulus-secretion coupling in rat basophilic leukaemia (RBL-2H3) cells transfected with the human C5a receptor is mediated by pertussis and cholera toxin-sensitive G proteins. Biochem Mol Biol Int 32: 13-20.
164. Monk PN, Pease JE, Marland G, Barker MD (1994b). Mutation of aspartate 82 of the human C5a receptor abolishes the secretory response to human C5a in transfected rat basophilic leukemia cells. Eur J Immunol 24: 2922-2925.
165. Moore KL (2003). The biology and enzymology of protein tyrosine O-sulfation. J Biol Chem 278: 24243-24246.
166. Morgan EL, Ember JA, Sanderson SD, Scholz W, Buchner R, Ye RD et al. (1993). Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor. J Immunol 151: 377-388.
167. Morgan EL, Thoman ML, Weigle WO, Hugli TE (1983). Anaphylatoxin-mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune responses. J Immunol 130: 1257-1261.
168. Mullaly SC, Kubes P (2007). Mast cell-expressed complement receptor, not TLR2, is the main detector of zymosan in peritonitis. Eur J Immunol 37: 224-234.
169. Mulligan MS, Schmid E, Beck-Schimmer B, Till GO, Friedl HP, Brauer RB et al. (1996). Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest 98: 503-512.
170. Naik N, Giannini E, Brouchon L, Boulay F (1997). Internalization and recycling of the C5a anaphylatoxin receptor: evidence that the agonist-mediated internalization is modulated by phosphorylation of the C-terminal domain. J Cell Sci 110 (Part 19): 2381-2390.
171. Nash SP, Heuertz RM (2005). Blockade of p38 map kinase inhibits complement-induced acute lung injury in a murine model. Int Immunopharmacol 5: 1870-1880.
172. Nataf S, Davoust N, Ames RS, Barnum SR (1999). Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 162: 4018-4023.
173. Nataf S, Levison SW, Barnum SR (2001). Expression of the anaphylatoxin C5a receptor in the oligodendrocyte lineage. Brain Res 894: 321-326.
174. Niederbichler AD, Hoesel LM, Westfall MV, Gao H, Ipaktchi KR, Sun L et al. (2006). An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med 203: 53-61.
175. Nishiura H, Shibuya Y, Matsubara S, Tanase S, Kambara T, Yamamoto T (1996). Monocyte chemotactic factor in rheumatoid arthritis synovial tissue. Probably a cross-linked derivative of S19 ribosomal protein. J Biol Chem 271: 878-882.
176. O'barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T et al. (2001). Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 166: 4154-4162.
177. Ochs HD, Notarangelo LD (2005). Structure and function of the Wiskott-Aldrich syndrome protein. Curr Opin Hematol 12: 284-291.
178. Ohno M, Hirata T, Enomoto M, Araki T, Ishimaru H, Takahashi TA (2000). A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol Immunol 37: 407-412.
179. Okada H, Silverman MS (1979). Chemotactic activity in periodontal disease. I. The role of complement in monocyte chemotaxis. J Periodontal Res 14: 20-25.
180. Okinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, Kinrade MB et al. (2003). C5L2, a nonsignaling C5A binding protein. Biochemistry 42: 9406-9415.
181. Olsen UB, Selmer J, Kahl JU (1988). Complement C5a receptor antagonism by protamine and poly-L-Arg on human leukocytes. Complement 5: 153-162.
182. Onuma H, Masuko-Hongo K, Yuan G, Sakata M, Nakamura H, Kato T et al. (2002). Expression of the anaphylatoxin receptor C5aR (CD88) by human articular chondrocytes. Rheumatol Int 22: 52-55.
183. Oppermann M, Gotze O (1994). Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. Immunology 82: 516-521.
184. Oppermann M, Raedt U, Hebell T, Schmidt B, Zimmermann B, Gotze O (1993). Probing the human receptor for C5a anaphylatoxin with site-directed antibodies. Identification of a potential ligand binding site on the NH2-terminal domain. J Immunol 151: 3785-3794.
185. Oskeritzian CA, Zhao W, Min HK, Xia HZ, Pozez A, Kiev J et al. (2005). Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell. J Allergy Clin Immunol 115: 1162-1168.
186. Otto M, Hawlisch H, Monk PN, Muller M, Klos A, Karp CL et al. (2004). C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J Biol Chem 279: 142-151.
187. Ottonello L, Corcione A, Tortolina G, Airoldi I, Albesiano E, Favre A et al. (1999). rC5a directs the in vitro migration of human memory and naive tonsillar B lymphocytes: implications for B cell trafficking in secondary lymphoid tissues. J Immunol 162: 6510-6517.
188. Pease JE, Burton DR, Barker MD (1994). Generation of chimeric C5a/ formyl peptide receptors: towards the identification of the human C5a receptor binding site. Eur J Immunol 24: 211-215.
189. Perianayagam MC, Balakrishnan VS, King AJ, Pereira BJ, Jaber BL (2002). C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway. Kidney Int 61: 456-463.
190. Perianayagam MC, Balakrishnan VS, Pereira BJ, Jaber BL (2004). C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase and Bad-mediated signalling pathway. Eur J Clin Invest 34: 50-56.
191. Perianayagam MC, Madias NE, Pereira BJ, Jaber BL (2006). CREB transcription factor modulates Bcl2 transcription in response to C5a in HL-60-derived neutrophils. Eur J Clin Invest 36: 353-361.
192. Piccolo MT, Wang Y, Sannomiya P, Piccolo NS, Piccolo MS, Hugli TE et al. (1999). Chemotactic mediator requirements in lung injury following skin burns in rats. Exp Mol Pathol 66: 220-226.
193. Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, Taylor SM (2004). Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol 142: 756-764.
194. Rahpeymai Y, Hietala MA, Wilhelmsson U, Fotheringham A, Davies I, Nilsson AK et al. (2006). Complement: a novel factor in basal and ischemia-induced neurogenesis. Embo J 25: 1364-1374.
195. Ratner M (2006). Complement inhibitors finally find orphan niches. Nat Biotechnol 24: 371-372.
196. Regal JF, Hardy TM, Casey FB, Chakrin LW (1983). Effects of C5a on guinea pig lung: histamine release and mechanism of contraction. Immunopharmacology 5: 315-327.
197. Reiman R, Gerard C, Campbell IL, Barnum SR (2002). Disruption of the C5a receptor gene fails to protect against experimental allergic encephalomyelitis. Eur J Immunol 32: 1157-1163.
198. Ribas C, Penela P, Murga C, Salcedo A, Garcia-Hoz C, Jurado-Pueyo M et al. (2007). The G protein-coupled receptor kinase (GRK) interactome: Role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta 1768: 913-942.
199. Riedemann NC, Guo RF, Bernacki KD, Reuben JS, Laudes IJ, Neff TA et al. (2003). Regulation by C5a of neutrophil activation during sepsis. Immunity 19: 193-202.
200. Riedemann NC, Guo RF, Laudes IJ, Keller K, Sarma VJ, Padgaonkar V . (2002a). C5a receptor and thymocyte apoptosis in sepsis. FASEB J 16: 887-888.
201. Riedemann NC, Guo RF, Sarma VJ, Laudes IJ, Huber-Lang M, Warner RL et al. (2002b). Expression and function of the C5a receptor in rat alveolar epithelial cells. J Immunol 168: 1919-1925.
202. Rousseau S, Dolado I, Beardmore V, Shpiro N, Marquez R, Nebreda AR et al. (2006). CXCL12 and C5a trigger cell migration via a PAK1/ 2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway. Cell Signal 18: 1897-1905.
203. Rubin J, Titus L, Nanes MS (1991). Regulation of complement 5a receptor expression in U937 cells by phorbol ester. J Leukoc Biol 50: 502-508.
204. Saatvedt K, Lindberg H, Geiran OR, Michelsen S, Pedersen T, Seem E et al. (1996). Ultrafiltration after cardiopulmonary bypass in children: effects on hemodynamics, cytokines and complement. Cardiovasc Res 31: 596-602.
205. Schieferdecker HL, Schlaf G, Koleva M, Gotze O, Jungermann K (2000). Induction of functional anaphylatoxin C5a receptors on hepatocytes by in vivo treatment of rats with IL-6. J Immunol 164: 5453-5458.
206. Schlaf G, Schmitz M, Heine I, Demberg T, Schieferdecker HL, Gotze O (2004). Upregulation of fibronectin but not of entactin, collagen IV and smooth muscle actin by anaphylatoxin C5a in rat hepatic stellate cells. Histol Histopathol 19: 1165-1174.
207. Schlaf G, Schmitz M, Rothermel E, Jungermann K, Schieferdecker HL, Gotze O (2003). Expression and induction of anaphylatoxin C5a receptors in the rat liver. Histol Histopathol 18: 299-308.
208. Schnatbaum K, Locardi E, Scharn D, Richter U, Hawlisch H, Knolle J et al. (2006). Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett 16: 5088-5092.
209. Schraufstatter IU, Trieu K, Sikora L, Sriramarao P, Discipio R (2002). Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol 169: 2102-2110.
210. Scola A-M, Higginbottom A, Partridge LJ, Reid C, Woodruff TM, Taylor SM et al. (2007). The role of the n-terminal domain of the complement fragment receptor, C5l2, in ligand binding. J Biol Chem 282: 3664-3671.
211. Sewell DL, Nacewicz B, Liu F, Macvilay S, Erdei A, Lambris JD et al. (2004). Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J Neuroimmunol 155: 55-63.
212. Sheth B, Banks P, Burton DR, Monk PN (1991). The regulation of actin polymerization in differentiating U937 cells correlates with increased membrane levels of the pertussis-toxin-sensitive G-protein Gi2. Biochem J 275 (Part 3): 809-811.
213. Short A, Wong AK, Finch AM, Haaima G, Shiels IA, Fairlie DP et al. (1999). Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br J Pharmacol 126: 551-554.
214. Shrestha A, Shi L, Tanase S, Tsukamoto M, Nishino N, Tokita K et al. (2004). Bacterial chaperone protein, Skp, induces leukocyte chemotaxis via C5a receptor. Am J Pathol 164: 763-772.
215. Shushakova N, Skokowa J, Schulman J, Baumann U, Zwirner J, Schmidt RE et al. (2002). C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest 110: 1823-1830.
216. Skokowa J, Ali SR, Felda O, Kumar V, Konrad S, Shushakova N et al. (2005). Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. J Immunol 174: 3041-3050.
217. Snyderman R, Phillips J, Mergenhagen SE (1970). Polymorphonuclear Leukocyte Chemotactic Activity in Rabbit Serum and Guinea Pig Serum Treated with Immune Complexes: Evidence for C5a as the Major Chemotactic Factor. Infect Immun 1: 521-525.
218. Snyderman R, Pike MC, Mccarley D, Lang L (1975). Quantification of mouse macrophage chemotaxis in vitro: role of C5 for the production of chemotactic activity. Infect Immun 11: 488-492.
219. Soruri A, Kiafard Z, Dettmer C, Riggert J, Kohl J, Zwirner J (2003a). IL-4 down-regulates anaphylatoxin receptors in monocytes and dendritic cells and impairs anaphylatoxin-induced migration in vivo. J Immunol 170: 3306-3314.
220. Soruri A, Kim S, Kiafard Z, Zwirner J (2003b). Characterization of C5aR expression on murine myeloid and lymphoid cells by the use of a novel monoclonal antibody. Immunol Lett 88: 47-52.
221. Stahel PF, Frei K, Eugster HP, Fontana A, Hummel KM, Wetsel RA et al. (1997). TNF-alpha-mediated expression of the receptor for anaphylatoxin C5a on neurons in experimental Listeria meningoencephalitis. J Immunol 159: 861-869.
222. Stahel PF, Kariya K, Shohami E, Barnum SR, Eugster H, Trentz O et al. (2000). Intracerebral complement C5a receptor (CD88) expression is regulated by TNF and lymphotoxin-alpha following closed head injury in mice. J Neuroimmunol 109: 164-172.
223. Strachan AJ, Shiels IA, Reid RC, Fairlie DP, Taylor SM (2001). Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist. Br J Pharmacol 134: 1778-1786.
224. Strachan AJ, Woodruff TM, Haaima G, Fairlie DP, Taylor SM (2000). A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J Immunol 164: 6560-6565.
225. Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE et al. (2003). The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 198: 913-923.
226. Sumichika H, Sakata K, Sato N, Takeshita S, Ishibuchi S, Nakamura M et al. (2002). Identification of a potent and orally active nonpeptide C5a receptor antagonist. J Biol Chem 277: 49403-49407.
227. Sun J, Ember JA, Chao TH, Fukuoka Y, Ye RD, Hugli TE (1999). Identification of ligand effector binding sites in transmembrane regions of the human G protein-coupled C3a receptor. Protein Sci 8: 2304-2311.
228. Surgand JS, Rodrigo J, Kellenberger E, Rognan D (2006). A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 62: 509-538.
229. Tardif M, Brouchon L, Rabiet MJ, Boulay F (2003). Direct binding of a fragment of the Wiskott-Aldrich syndrome protein to the C-terminal end of the anaphylatoxin C5a receptor. Biochem J 372: 453-463.
230. Taylor SM, Fairlie DP (2005). Discovery of potent cyclic antagonists of human C5a receptors. In: Morikis D and Lambris JD (eds). Structural Biology of the Complement System. CRC Press: New York, pp 341-362.
231. Thurman JM, Holers VM (2006). The central role of the alternative complement pathway in human disease. J Immunol 176: 1305-1310.
232. Tofukuji M, Stahl GL, Agah A, Metais C, Simons M, Sellke FW (1998). Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. J Thorac Cardiovasc Surg 116: 1060-1068.
233. Tsuji RF, Kawikova I, Ramabhadran R, Akahira-Azuma M, Taub D, Hugli TE et al. (2000). Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J Immunol 165: 1588-1598.
234. Tsuji RF, Yamakoshi J, Uramoto M, Koshino H, Saito M, Kikuchi M et al. (1995). Anti-inflammatory effects and specificity of L-156,602: comparison of effects on concanavalin A and zymosan-induced footpad edema, and contact sensitivity response. Immunopharmacology 29: 79-87.
235. Van Beek J, Elward K, Gasque P (2003). Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann N Y Acad Sci 992: 56-71.
236. Van Epps DE, Chenoweth DE (1984). Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes. J Immunol 132: 2862-2867.
237. Van Epps DE, Simpson S, Bender JG, Chenoweth DE (1990). Regulation of C5a and formyl peptide receptor expression on human polymorphonuclear leukocytes. J Immunol 144: 1062-1068.
238. Vollmers HP, Brandlein S (2006). Natural IgM antibodies: the orphaned molecules in immune surveillance. Adv Drug Deliv Rev 58: 755-765.
239. Waters SM, Brodbeck RM, Steflik J, Yu J, Baltazar C, Peck AE et al. (2005). Molecular characterization of the gerbil c5a receptor and identification of a transmembrane domain v amino Acid that is crucial for small molecule antagonist interaction. J Biol Chem 280: 40617-40623.
240. Weinmann O, Gutzmer R, Zwirner J, Wittmann M, Langer K, Lisewski M et al. (2003). Up-regulation of C5a receptor expression and function on human monocyte derived dendritic cells by prostaglandin E2. Immunology 110: 458-465.
241. Weisman HF, Bartow T, Leppo MK, Boyle MP, Marsh Jr HC, Carson GR et al. (1990). Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians 103: 64-72.
242. Welch TR, Frenzke M, Witte D, Davis AE (2002). C5a is important in the tubulointerstitial component of experimental immune complex glomerulonephritis. Clin Exp Immunol 130: 43-48.
243. Wong AK, Finch AM, Pierens GK, Craik DJ, Taylor SM, Fairlie DP (1998). Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a. J Med Chem 41: 3417-3425.
244. Wong AK (1999b). PhD Thesis, University of Queensland.
245. Wong AK, Taylor SM, Fairlie DP (1999a). Development of C5a receptor antagonists. IDrugs 2: 686-693.
246. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM (2003). A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol 171: 5514-5520.
247. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM (2004). Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. J Surg Res 116: 81-90.
248. Woodruff TM, Crane JW, Proctor LM, Buller KM, Shek AB, De Vos K et al. (2006). Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J 20: 1407-1417.
249. Woodruff TM, Strachan AJ, Dryburgh N, Shiels IA, Reid RC, Fairlie DP et al. (2002). Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum 46: 2476-2485.
250. Woodruff TM, Strachan AJ, Sanderson SD, Monk PN, Wong AK, Fairlie DP et al. (2001). Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation 25: 171-177.
251. Yamamoto T (2007). Roles of the ribosomal protein S19 dimer and the C5a receptor in pathophysiological functions of phagocytic leukocytes. Pathol Int 57: 1-11.
252. Yao J, Harvath L, Gilbert DL, Colton CA (1990). Chemotaxis by a CNS macrophage, the microglia. J Neurosci Res 27: 36-42.
253. Yuan G, Wei J, Zhou J, Hu H, Tang Z, Zhang G (2003). Expression of C5aR (CD88) of synoviocytes isolated from patients with rheumatoid arthritis and osteoarthritis. Chin Med J (England) 116: 1408-1412.
254. Zahn S, Zwirner J, Spengler HP, Gotze O (1997). Chemoattractant receptors for interleukin-8 and C5a: expression on peripheral blood leukocytes and differential regulation on HL-60 and AML-193 cells by vitamin D3 and all-trans retinoic acid. Eur J Immunol 27: 935-940.
255. Zhang X, Boyar W, Toth MJ, Wennogle L, Gonnella NC (1997). Structural definition of the C5a C terminus by two-dimensional nuclear magnetic resonance spectroscopy. Proteins 28: 261-267.
256. Zhu Y, Thangamani S, Ho B, Ding JL (2005). The ancient origin of the complement system. EMBO J 24: 382-394.
257. Zuiderweg ER, Fesik SW (1989). Heteronuclear three-dimensional NMR spectroscopy of the inflammatory protein C5a. Biochemistry 28: 2387-2391.
258. Zuiderweg ER, Nettesheim DG, Mollison KW, Carter GW (1989). Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data. Biochemistry 28: 172-185.
259. Zwirner J, Fayyazi A, Gotze O (1999). Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 36: 877-884.